Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1995 Dec 5;92(25):11558–11562. doi: 10.1073/pnas.92.25.11558

The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation.

S Sato 1, D A Steeber 1, T F Tedder 1
PMCID: PMC40441  PMID: 8524803

Abstract

The phenotypes of CD19-deficient (CD19-/-) mice, and human CD19-transgenic (hCD19TG) mice that overexpress CD19 indicate that CD19 is a response regulator of B-lymphocyte surface receptor signaling. To further characterize the function of CD19 during B-cell differentiation, humoral immune responses to a T-cell-independent type 1 [trinitrophenyl-lipopolysaccharide (TNP-LPS)], a T-cell-independent type 2 [dinitrophenyl (DNP)-Ficoll], and a T-cell-dependent [DNP-keyhole limpet hemocyanin (KLH)] antigen were assessed in CD19-/- and hCD19TG mice. B cells from CD19-/- mice differentiated and underwent immunoglobulin isotype switching in vitro in response to mitogens and cytokines. In vivo, CD19-/- mice generated humoral responses to TNP-LPS and DNP-KLH that were dramatically lower than those of wild-type littermates. Surprisingly, the humoral response to DNP-Ficoll was significantly greater in CD19-/- mice. In contrast, hCD19TG mice were hyperresponsive to TNP-LPS and DNP-KLH immunization but were hyporesponsive to DNP-Ficoll. These results demonstrate that CD19 is not required for B-cell differentiation and isotype switching but serves as a response regulator which modulates B-cell differentiation. Since humoral responses to both T-cell-dependent and T-cell-independent antigens were similarly affected by alterations in CD19 expression, these differences are most likely to result from intrinsic changes in B-cell function rather than from the selective disruption of B-cell interactions with T cells.

Full text

PDF
11558

Images in this article

11559Fig. 1
on p.11559
11562Fig. 5
on p.11562

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrett T. B., Shu G. L., Draves K. E., Pezzutto A., Clark E. A. Signaling through CD19, Fc receptors or transforming growth factor-beta: each inhibits the activation of resting human B cells differently. Eur J Immunol. 1990 May;20(5):1053–1059. doi: 10.1002/eji.1830200516. [DOI] [PubMed] [Google Scholar]
  2. Bradbury L. E., Kansas G. S., Levy S., Evans R. L., Tedder T. F. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol. 1992 Nov 1;149(9):2841–2850. [PubMed] [Google Scholar]
  3. Carter R. H., Fearon D. T. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science. 1992 Apr 3;256(5053):105–107. doi: 10.1126/science.1373518. [DOI] [PubMed] [Google Scholar]
  4. Carter R. H., Tuveson D. A., Park D. J., Rhee S. G., Fearon D. T. The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. J Immunol. 1991 Dec 1;147(11):3663–3671. [PubMed] [Google Scholar]
  5. Engel P., Zhou L. J., Ord D. C., Sato S., Koller B., Tedder T. F. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 1995 Jul;3(1):39–50. doi: 10.1016/1074-7613(95)90157-4. [DOI] [PubMed] [Google Scholar]
  6. Fearon D. T., Carter R. H. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol. 1995;13:127–149. doi: 10.1146/annurev.iy.13.040195.001015. [DOI] [PubMed] [Google Scholar]
  7. Förster I., Rajewsky K. Expansion and functional activity of Ly-1+ B cells upon transfer of peritoneal cells into allotype-congenic, newborn mice. Eur J Immunol. 1987 Apr;17(4):521–528. doi: 10.1002/eji.1830170414. [DOI] [PubMed] [Google Scholar]
  8. Hardy R. R., Carmack C. E., Li Y. S., Hayakawa K. Distinctive developmental origins and specificities of murine CD5+ B cells. Immunol Rev. 1994 Feb;137:91–118. doi: 10.1111/j.1600-065x.1994.tb00660.x. [DOI] [PubMed] [Google Scholar]
  9. Haughton G., Arnold L. W., Whitmore A. C., Clarke S. H. B-1 cells are made, not born. Immunol Today. 1993 Feb;14(2):84–91. doi: 10.1016/0167-5699(93)90064-R. [DOI] [PubMed] [Google Scholar]
  10. Herzenberg L. A., Herzenberg L. A. Toward a layered immune system. Cell. 1989 Dec 22;59(6):953–954. doi: 10.1016/0092-8674(89)90748-4. [DOI] [PubMed] [Google Scholar]
  11. Kansas G. S., Tedder T. F. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J Immunol. 1991 Dec 15;147(12):4094–4102. [PubMed] [Google Scholar]
  12. Kantor A. B. The development and repertoire of B-1 cells (CD5 B cells). Immunol Today. 1991 Nov;12(11):389–391. doi: 10.1016/0167-5699(91)90136-H. [DOI] [PubMed] [Google Scholar]
  13. Mond J. J., Lees A., Snapper C. M. T cell-independent antigens type 2. Annu Rev Immunol. 1995;13:655–692. doi: 10.1146/annurev.iy.13.040195.003255. [DOI] [PubMed] [Google Scholar]
  14. Nadler L. M., Anderson K. C., Marti G., Bates M., Park E., Daley J. F., Schlossman S. F. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol. 1983 Jul;131(1):244–250. [PubMed] [Google Scholar]
  15. Pezzutto A., Dörken B., Rabinovitch P. S., Ledbetter J. A., Moldenhauer G., Clark E. A. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol. 1987 May 1;138(9):2793–2799. [PubMed] [Google Scholar]
  16. Rickert R. C., Rajewsky K., Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature. 1995 Jul 27;376(6538):352–355. doi: 10.1038/376352a0. [DOI] [PubMed] [Google Scholar]
  17. Rigley K. P., Callard R. E. Inhibition of B cell proliferation with anti-CD19 monoclonal antibodies: anti-CD19 antibodies do not interfere with early signaling events triggered by anti-IgM or interleukin 4. Eur J Immunol. 1991 Mar;21(3):535–540. doi: 10.1002/eji.1830210302. [DOI] [PubMed] [Google Scholar]
  18. Rijkers G. T., Griffioen A. W., Zegers B. J., Cambier J. C. Ligation of membrane immunoglobulin leads to inactivation of the signal-transducing ability of membrane immunoglobulin, CD19, CD21, and B-cell gp95. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8766–8770. doi: 10.1073/pnas.87.22.8766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rolink A., Melchers F. Molecular and cellular origins of B lymphocyte diversity. Cell. 1991 Sep 20;66(6):1081–1094. doi: 10.1016/0092-8674(91)90032-t. [DOI] [PubMed] [Google Scholar]
  20. Snapper C. M., Mond J. J. Towards a comprehensive view of immunoglobulin class switching. Immunol Today. 1993 Jan;14(1):15–17. doi: 10.1016/0167-5699(93)90318-F. [DOI] [PubMed] [Google Scholar]
  21. Tedder T. F., Isaacs C. M. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J Immunol. 1989 Jul 15;143(2):712–717. [PubMed] [Google Scholar]
  22. Tedder T. F., Zhou L. J., Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today. 1994 Sep;15(9):437–442. doi: 10.1016/0167-5699(94)90274-7. [DOI] [PubMed] [Google Scholar]
  23. Tuveson D. A., Carter R. H., Soltoff S. P., Fearon D. T. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science. 1993 May 14;260(5110):986–989. doi: 10.1126/science.7684160. [DOI] [PubMed] [Google Scholar]
  24. Uckun F. M., Burkhardt A. L., Jarvis L., Jun X., Stealey B., Dibirdik I., Myers D. E., Tuel-Ahlgren L., Bolen J. B. Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J Biol Chem. 1993 Oct 5;268(28):21172–21184. [PubMed] [Google Scholar]
  25. Uckun F. M., Ledbetter J. A. Immunobiologic differences between normal and leukemic human B-cell precursors. Proc Natl Acad Sci U S A. 1988 Nov;85(22):8603–8607. doi: 10.1073/pnas.85.22.8603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Weng W. K., Jarvis L., LeBien T. W. Signaling through CD19 activates Vav/mitogen-activated protein kinase pathway and induces formation of a CD19/Vav/phosphatidylinositol 3-kinase complex in human B cell precursors. J Biol Chem. 1994 Dec 23;269(51):32514–32521. [PubMed] [Google Scholar]
  27. Zhou L. J., Ord D. C., Hughes A. L., Tedder T. F. Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig B lymphocytes. Conservation of the extensive cytoplasmic domain. J Immunol. 1991 Aug 15;147(4):1424–1432. [PubMed] [Google Scholar]
  28. Zhou L. J., Smith H. M., Waldschmidt T. J., Schwarting R., Daley J., Tedder T. F. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development. Mol Cell Biol. 1994 Jun;14(6):3884–3894. doi: 10.1128/mcb.14.6.3884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. van Noesel C. J., Lankester A. C., van Lier R. A. Dual antigen recognition by B cells. Immunol Today. 1993 Jan;14(1):8–11. doi: 10.1016/0167-5699(93)90316-d. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES